A Double-Blind, Placebo-Controlled, Fixed-Dose Study of AGN-241751 in Adult Participants With Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs AGN-241751 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Allergan
- 23 Jul 2019 Planned End Date changed from 15 Aug 2019 to 18 Aug 2019.
- 23 Jul 2019 Planned primary completion date changed from 19 Jul 2019 to 18 Aug 2019.
- 19 Jul 2019 Status changed to active, no longer recruting.